Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in ACADIA Pharmaceuticals Inc. or Fortrea Holdings Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how ACADIA Pharmaceuticals Inc. and Fortrea Holdings Inc. compare based on key financial metrics to determine which better meets your investment needs.

About ACADIA Pharmaceuticals Inc. and Fortrea Holdings Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer’s disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington’s disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Latest Biotechnology and ACADIA Pharmaceuticals Inc., Fortrea Holdings Inc. Stock News

As of July 30, 2026, ACADIA Pharmaceuticals Inc. had a $4.5 billion market capitalization, compared to the Biotechnology median of $251.9 million. ACADIA Pharmaceuticals Inc.’s stock is down 3.1% in 2026, up 4.1% in the previous five trading days and up 17.32% in the past year.

Currently, ACADIA Pharmaceuticals Inc.’s price-earnings ratio is 12.1. ACADIA Pharmaceuticals Inc.’s trailing 12-month revenue is $1.1 billion with a 34.3% net profit margin. Year-over-year quarterly sales growth most recently was 9.7%. Analysts expect adjusted earnings to reach $0.367 per share for the current fiscal year. ACADIA Pharmaceuticals Inc. does not currently pay a dividend.

As of July 30, 2026, Fortrea Holdings Inc. had a $1.8 billion market cap, putting it in the 52nd percentile of all stocks. Fortrea Holdings Inc.’s stock is up 11.1% in 2026, down 1.8% in the previous five trading days and up 199.53% in the past year.

Currently, Fortrea Holdings Inc. does not have a price-earnings ratio. Fortrea Holdings Inc.’s trailing 12-month revenue is $2.7 billion with a -3.2% net profit margin. Year-over-year quarterly sales growth most recently was -2.3%. Analysts expect adjusted earnings to reach $0.829 per share for the current fiscal year. Fortrea Holdings Inc. does not currently pay a dividend.

How We Compare ACADIA Pharmaceuticals Inc. and Fortrea Holdings Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at ACADIA Pharmaceuticals Inc. and Fortrea Holdings Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

ACADIA Pharmaceuticals Inc. and Fortrea Holdings Inc. Stock Value Grades

Company	Ticker	Value
ACADIA Pharmaceuticals Inc.	ACAD	D
Fortrea Holdings Inc.	FTRE	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

ACADIA Pharmaceuticals Inc. has a Value Score of 24, which is Expensive. Fortrea Holdings Inc. has a Value Score of 42, which is Average.

The Value Stock Winner: No Clear Winner

Neither ACADIA Pharmaceuticals Inc. or Fortrea Holdings Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if ACADIA Pharmaceuticals Inc. or Fortrea Holdings Inc. is the better investment when it comes to value.

ACADIA Pharmaceuticals Inc. and Fortrea Holdings Inc.’s Momentum Grades

Company	Ticker	Momentum
ACADIA Pharmaceuticals Inc.	ACAD	B
Fortrea Holdings Inc.	FTRE	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

ACADIA Pharmaceuticals Inc. has a Momentum Score of 62, which is Strong. Fortrea Holdings Inc. has a Momentum Score of 98, which is Very Strong.

The Momentum Grade Winner: Fortrea Holdings Inc.

As you can clearly see from the Momentum Grade breakdown above, Fortrea Holdings Inc. is considered to have stronger momentum compared to ACADIA Pharmaceuticals Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Fortrea Holdings Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

ACADIA Pharmaceuticals Inc. and Fortrea Holdings Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
ACADIA Pharmaceuticals Inc.	ACAD	F
Fortrea Holdings Inc.	FTRE	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

ACADIA Pharmaceuticals Inc. has a Earnings Estimate Score of 17, which is Very Negative. Fortrea Holdings Inc. has a Earnings Estimate Score of 77, which is Positive.

The Earnings Estimate Revisions Grade Winner: Fortrea Holdings Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Fortrea Holdings Inc. has a better Earnings Estimate Revisions Grade than ACADIA Pharmaceuticals Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Fortrea Holdings Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other ACADIA Pharmaceuticals Inc. and Fortrea Holdings Inc. Grades

In addition to Momentum, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether ACADIA Pharmaceuticals Inc. and Fortrea Holdings Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, ACADIA Pharmaceuticals Inc. or Fortrea Holdings Inc. Stock?

Overall, ACADIA Pharmaceuticals Inc. stock has a Value Score of 24, Momentum Score of 62 and Estimate Revisions Score of 17.

Fortrea Holdings Inc. stock has a Value Score of 42, Momentum Score of 98 and Estimate Revisions Score of 77.

Comparing ACADIA Pharmaceuticals Inc. and Fortrea Holdings Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.